DJIA 17,172.68 -107.06 -0.62%
NASDAQ 4,527.69 -52.10 -1.14%
S&P 500 1,994.29 -16.11 -0.80%
market minute promo

Prosensa Holding B.V. (NASDAQ: RNA)

8.29 -0.37 (-4.27%)

Quote as of


company name or ticker

Recent Quotes

RNA $8.29 -4.27%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $8.59
Previous Close $8.66
Daily Range $8.16 - $8.63
52-Week Range $3.43 - $13.32
Market Cap $297.9M
P/E Ratio 0.00
Dividend (Yield) $0.00 (0.0%)
Volume 111,882
Average Daily Volume 107,835
Current FY EPS -$0.69

Sector

Industry

Prosensa Holding B.V. (RNA) Description

Prosensa Holding B.V. Website: http://www.prosensa.eu/

News & Commentary

Why Sarepta Therapeutics Inc. Stock Soared By 17% in 2014

Sarepta Therapeutics stock has been whipsawed over the past year. Find out what's been the cause of its volatility and whether or not the stock can head higher.

George Soros Is Betting on This Risky Stock: Should You?

Sarepta Therapeutics is a clinical-stage biotechnology company seeking to gain approval for a potentially game-changing Duchenne muscular dystrophy drug called eteplirsen. Wall Street appears convinced that the drug is a winner, but scientists have been less optimistic. Here's why.

Why You Shouldn't Bet Against Prosensa (RNA) Stock - Tale of the Tape

Prosensa Holding's (RNA) CEO Hans Schikan on Q2 2014 Results - Earnings Call Transcript

Should You Buy Prosensa Holding (RNA) Ahead of Earnings? - Tale of the Tape

Should You Buy Prosensa Holding (RNA) Ahead of Earnings? - Tale of the Tape

3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP

3 Stocks Crushed by the Market This Week

These health-care stocks experienced a horrendous week -- with each plunging more than 20%.

3 Reasons Not to Worry About Sarepta Therapeutics Inc.

Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.

Should Sarepta's Shares Be Tumbling?

Sarepta has updated data from eteplirsen's trial in Duchenne's muscular dystrophy, potentially positioning it to compete against Prosensa's drisapersen and PTC Therapeutics Translarna.

Down 17%: Is Sarepta a Bad News Buy?

Sarepta Therapeutics is down over 20% today on disappointing clinical trial news. Here's what you need to know.

See More RNA News...